U.S. Markets close in 2 hrs 55 mins
  • S&P 500

    3,467.49
    -16.32 (-0.47%)
     
  • Dow 30

    28,509.02
    -97.29 (-0.34%)
     
  • Nasdaq

    11,633.09
    -38.47 (-0.33%)
     
  • Russell 2000

    1,637.51
    +3.70 (+0.23%)
     
  • Crude Oil

    40.97
    +0.09 (+0.22%)
     
  • Gold

    1,913.00
    +6.60 (+0.35%)
     
  • Silver

    24.70
    +0.30 (+1.21%)
     
  • EUR/USD

    1.1788
    +0.0061 (+0.5187%)
     
  • 10-Yr Bond

    0.7610
    +0.0170 (+2.28%)
     
  • Vix

    27.84
    +0.43 (+1.57%)
     
  • GBP/USD

    1.2985
    +0.0077 (+0.5960%)
     
  • USD/JPY

    105.3920
    -0.0020 (-0.0019%)
     
  • BTC-USD

    11,758.32
    +701.31 (+6.34%)
     
  • CMC Crypto 200

    239.87
    +6.20 (+2.65%)
     
  • FTSE 100

    5,884.65
    -34.93 (-0.59%)
     
  • Nikkei 225

    23,671.13
    +260.50 (+1.11%)
     

Did You Manage To Avoid Organogenesis Holdings's (NASDAQ:ORGO) 45% Share Price Drop?

Simply Wall St
·3 mins read

It's easy to match the overall market return by buying an index fund. While individual stocks can be big winners, plenty more fail to generate satisfactory returns. Unfortunately the Organogenesis Holdings Inc. (NASDAQ:ORGO) share price slid 45% over twelve months. That's disappointing when you consider the market returned 23%. Organogenesis Holdings may have better days ahead, of course; we've only looked at a one year period. Shareholders have had an even rougher run lately, with the share price down 39% in the last 90 days.

View our latest analysis for Organogenesis Holdings

Organogenesis Holdings isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

Organogenesis Holdings grew its revenue by 37% over the last year. That's definitely a respectable growth rate. Meanwhile, the share price is down 45% over twelve months, which is disappointing given the progress made. You might even wonder if the share price was previously over-hyped. But if revenue keeps growing, then at a certain point the share price would likely follow.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

NasdaqCM:ORGO Income Statement, February 11th 2020
NasdaqCM:ORGO Income Statement, February 11th 2020

We consider it positive that insiders have made significant purchases in the last year. Even so, future earnings will be far more important to whether current shareholders make money. You can see what analysts are predicting for Organogenesis Holdings in this interactive graph of future profit estimates.

A Different Perspective

While Organogenesis Holdings shareholders are down 45% for the year, the market itself is up 23%. While the aim is to do better than that, it's worth recalling that even great long-term investments sometimes underperform for a year or more. With the stock down 39% over the last three months, the market doesn't seem to believe that the company has solved all its problems. Basically, most investors should be wary of buying into a poor-performing stock, unless the business itself has clearly improved. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For instance, we've identified 3 warning signs for Organogenesis Holdings (1 shouldn't be ignored) that you should be aware of.

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.